{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:38:34Z","timestamp":1787697514538,"version":"build-2784847793"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T00:00:00Z","timestamp":1545436800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008368","name":"Danish Rheumatism Association","doi-asserted-by":"publisher","award":["R159-A5111-B1265"],"award-info":[{"award-number":["R159-A5111-B1265"]}],"id":[{"id":"10.13039\/100008368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Forward Pharma"},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate temporal trends in the incidence and prevalence of gout in the adult Danish population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the nationwide Danish National Patient Registry, we calculated the number of incident gout patients (per 100 000 person-years) within each 1 year period from 1995 to 2015 and the prevalence of gout in 2000 and 2015. Further, we calculated age- and gender-specific incidence rates of gout from 1995 to 2015.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified a total of 45 685 incident gout patients (72.9% males) with a mean age of 65 years (s.d. 16) at diagnosis. In both genders, an increase in age-standardized incidence rates was observed from 32.3\/100 000 (95% CI 30.7, 33.9) in 1995 to 57.5\/100 000 (95% CI 55.6, 59.5) in 2015 (P &lt; 0.001). Similar trends were observed for 8950 cases diagnosed in rheumatology departments. We likewise observed an increase in the prevalence of gout from 0.29% (95% CI 0.29, 0.30) in 2000 to 0.68% (95% CI 0.68, 0.69) in 2015.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The annual incidence rate of gout increased by almost 80% in Denmark between 1995 and 2015. The prevalence increased by nearly 130% between 2000 and 2015. Reasons for this are unknown but may include an increase in risk factors (e.g. obesity, diabetes mellitus), longer life expectancy and increased awareness of the disease among patients and\/or health professionals.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/key390","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T07:42:42Z","timestamp":1542094962000},"page":"836-839","source":"Crossref","is-referenced-by-count":53,"title":["Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study"],"prefix":"10.1093","volume":"58","author":[{"given":"Kristian","family":"Zobbe","sequence":"first","affiliation":[{"name":"Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte University Hospital, Hellerup"},{"name":"Bispebjerg and Frederiksberg Hospital, Parker Institute, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Prieto-Alhambra","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK"},{"name":"Idiap Jordi Gol, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Cordtz","sequence":"additional","affiliation":[{"name":"Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte University Hospital, Hellerup"},{"name":"Bispebjerg and Frederiksberg Hospital, Parker Institute, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pil","family":"H\u00f8jgaard","sequence":"additional","affiliation":[{"name":"Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte University Hospital, Hellerup"},{"name":"Bispebjerg and Frederiksberg Hospital, Parker Institute, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Sk\u00f8t","family":"Hindrup","sequence":"additional","affiliation":[{"name":"Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte University Hospital, Hellerup"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Erik","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Bispebjerg and Frederiksberg Hospital, Parker Institute, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[{"name":"Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte University Hospital, Hellerup"},{"name":"Bispebjerg and Frederiksberg Hospital, Parker Institute, Frederiksberg, Denmark"},{"name":"Department of Rheumatology, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,19]]},"reference":[{"key":"2019081609504340100_key390-B1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence, and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2019081609504340100_key390-B2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-016-1062-6","article-title":"Incidence and prevalence of gout in Western Sweden","volume":"18","author":"Dehlin","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2019081609504340100_key390-B3","doi-asserted-by":"crossref","first-page":"e000326","DOI":"10.1136\/rmdopen-2016-000326","article-title":"Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective","volume":"2","author":"Kapetanovic","year":"2016","journal-title":"RMD Open"},{"key":"2019081609504340100_key390-B4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ije\/5.2.153","article-title":"Occurrence of gout in Copenhagen males aged 40\u201359","volume":"5","author":"De Muckadell","year":"1976","journal-title":"Int J Epidemiol"},{"key":"2019081609504340100_key390-B5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE)","volume":"18","author":"Vandenbroucke","year":"2007","journal-title":"Epidemiology"},{"key":"2019081609504340100_key390-B6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiology"},{"key":"2019081609504340100_key390-B7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"2019081609504340100_key390-B8","unstructured":"Association of the Nordic Cancer Registries. NORDCAN.http:\/\/www-dep.iarc.fr\/nordcan.htm (11 July 2017, last date accessed)."},{"key":"2019081609504340100_key390-B9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2011-201254","article-title":"Epidemiology of gout and hyperuricaemia in Italy during the years 2005\u20132009: a nationwide population-based study","volume":"72","author":"Trifir\u00f2","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2019081609504340100_key390-B10","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar3272","article-title":"Contemporary epidemiology of gout in the UK general population","volume":"13","author":"Cea Soriano","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2019081609504340100_key390-B11","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2019081609504340100_key390-B12","unstructured":"The Danish Society for Rheumatology. http:\/\/www.danskreumatologiskselskab.dk\/ (1 December 2017, date last accessed)."},{"key":"2019081609504340100_key390-B13","first-page":"54","article-title":"Prevalence of self-reported rheumatic diseases in a Portuguese population","volume":"39","author":"Reis","year":"2017","journal-title":"Acta Reumatol Port"},{"key":"2019081609504340100_key390-B14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1471-2474-11-98","article-title":"The prevalence of rheumatic diseases in central Greece: a population survey","volume":"11","author":"Anagnostopoulos","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"2019081609504340100_key390-B15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2019081609504340100_key390-B16","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/ard.2009.109884","article-title":"Menopause, postmenopausal hormone use and risk of incident gout","volume":"69","author":"Hak","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2019081609504340100_key390-B17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2288-11-83","article-title":"The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients","volume":"11","author":"Thygesen","year":"2011","journal-title":"BMC Med Res Methodol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/5\/836\/28719752\/key390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T14:47:17Z","timestamp":1569163637000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/5\/836\/5253845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,19]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,12,19]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key390","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2018,12,19]]}}}